Original research

Emerging molecular markers for the prognosis of differentiated thyroid cancer patients

Enke Baldini [a], Salvatore Sorrenti [b], Chiara Tuccilli [a], Natalie Prinzi [a], Carmela Coccaro [a], Antonio Catania [b], Angelo Filippini [b], Marco Bononi [c], Enrico De Antoni [b], Massimino D'Armiento [a], Salvatore Ulisse [a, *]

[a] Department of Experimental Medicine, "Sapienza" University of Rome, Viale Regina Elena 324, 00161 Rome, Italy
[b] Department of Surgical Sciences, "Sapienza" University of Rome, Italy
[c] Department of Surgery "Pietro Valdoni", "Sapienza" University of Rome, Italy

ARTICLE INFO

ABSTRACT

Epithelial thyroid cancers are represented by the differentiated papillary and follicular thyroid carcinomas which, following dedifferentiation, are thought to give rise to the highly aggressive and incurable anaplastic thyroid carcinomas. Although derived from the same cell type, the different thyroid tumors show specific histological features, biological behavior and degree of differentiation as a consequence of different genetic alterations. Over the last few years, our knowledge regarding the molecular alterations underlying thyroid cell malignant transformation and cancer progression has considerably increased; however, the prognosis of differentiated thyroid cancer patients still relies on high-risk clinic-pathological variables. In particular, the actual staging systems provides only a rough prediction for cancer mortality and risk of recurrences, including in each risk group patients with highly different tumor-specific progression, disease-free interval and survival time. In order to improve DTC patient's risk stratification, both the European and the American Thyroid Associations proposed practical guidelines to integrate the actual staging systems with additional clinical features such as the tumor histological variant, the results of post-ablative whole body scan and the serum thyroglobulin levels. Despite that, patients within the same risk group still show a very heterogeneous behavior in terms of disease-free interval. As a consequence, the identification of new prognostic molecular biomarkers able to testify tumor aggressiveness is highly required. Here we'll review recently characterized new molecular markers potentially able to ameliorate the prognosis in DTC patients.

© 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.

1. Thyroid cancer

Differentiated epithelial thyroid cancers (DTC) account for about 90–95% of all thyroid cancers and represent in the United States the fifth most common cancer in women [1,2]. The incidence of DTC has been increasing over the last decades, mainly as a result of the increasing ability to diagnose malignant transformation in small non-palpable nodules [3,4]. The DTC comprise two main histological entities, the follicular (FTC) and the papillary (PTC) thyroid carcinomas, which following dedifferentiation are assumed to generate the poorly DTC (PDTC) and the highly aggressive anaplastic thyroid carcinomas (ATC) unresponsive to any therapeutic agent [5,6]. Initial

DTC treatment includes total thyroidectomy followed, in most patients, by adjuvant therapy with ^{131}I [7–9]. Patient's follow-up embraces radioiodine scanning 6–12 months after surgery, periodic ultrasound of the thyroid bed and cervical lymph node compartments, measurement of basal and recombinant human TSH-stimulated thyroglobulin (Tg) serum level [7–9].

2. Molecular events involved in thyroid cancer progression

Progression of human cancers, including DTC, is characterized by malignant cell acquisition of novel functional capabilities, which include self-sufficiency in growth signals, insensitivity to anti-growth signals, evasion of apoptosis, limitless replicative potential, sustained angiogenesis, tissue invasion and metastasis [10]. In particular, relevant molecular alterations encountered in thyroid cancer progression responsible for the acquisition of the above

* Corresponding author.
  E-mail address: salvatore.ulisse@uniroma1.it (S. Ulisse).

mentioned capabilities comprise gene rearrangements of tyrosine kinase receptors, such as the RET/PTC and NTRK1 (neurotrophic receptor-tyrosine kinase 1), or activating point mutations of proteins mediating cellular responses to growth and differentiation signals, including RAS and BRAF, or the oncogenic fusion protein PAX8-PPARγ, that suppresses wild-type PPARγ function in a dominant-negative manner [11,12]. Genomic instability, a hallmark of solid tumors including the DTC, is thought to represent the mean by which premalignant cells may acquire these new capabilities [10,13]. As in many other cancer types, also in thyroid cancer the number and the frequency of chromosomal abnormalities observed increase from the DTC to the poorly differentiated thyroid carcinoma (PDTC) and ATC [14,15]. It is worth to note that alterations in the expression of several mitotic kinases responsible for correct chromosome segregation have been described in both DTC and ATC, and are thought to play a central role in the establishment of genomic instability [14–17]. These include the Polo-like kinase 1 and the three members of the Aurora kinase family [18–20].

The conversion of early-stage thyroid tumors to more aggressive and invasive malignancies occurs through an epithelial-to-mesenchymal transition (EMT), which implies the loss of cell–cell contacts, remodeling of cytoskeleton, and the acquisition of a migratory phenotype [21,22]. Abnormal expression of integrins, Notch, MET, TGFβ, NF-κB, PI3K, TWIST1, matrix metalloproteinases (MMP), components of the urokinase plasminogen activating system and p21-activated kinase (Pak), involved in the EMT, have been identified in PTC progression [21,22].

3. The prognosis of differentiated thyroid cancer patients

Differentiated thyroid cancer patients usually have a favorable prognosis, with 10-years-survival rate of approximately 90%. Nevertheless, about 20% of them face the morbidity of disease recurrence and DTC-related deaths [1,2,23–25]. Despite the increasing knowledge of the molecular processes responsible for thyroid cell malignant transformation and cancer progression, to date, the prognosis of thyroid cancer patients still relies on high-risk clinic-pathological variables such as patient's age, tumor size, histology, lymph nodal or distant metastasis [26,27]. In particular, the TNM (Tumor size, lymph Node and distant Metastasis) system developed by the American Joint Committee on Cancer and the International Union Against Cancer is the most widely used staging system for thyroid cancer patients [28]. This staging system is strongly influenced by the patient's age, with those above 45 yr receiving a worse prognosis despite other factors being equal [28]. The TNM, as well as other staging systems proposed by recognized international organizations, are capable to make a rough prediction of the high or low risk of cancer mortality leaving, however, in the same risk group patients showing different disease-specific progression and survival time. Similarly, they fail to predict the risk of cancer recurrences [29]. Both the European (ETA) and the American Thyroid Associations (ATA) proposed practical guidelines to estimate the risk of recurrences in which the TNM parameters are integrated by additional clinical features such as the tumor histological variant, the results of post-ablative whole body scan and the serum Tg levels [9,24]. Despite that, patients included in the same risk group still show a very heterogeneous behavior in terms of disease-free interval. In addition, the stratification risk proposed by the ATA and the ETA is not accurate in predicting the long-term outcome in DTC patients, having a very low positive predictive value [30]. As a consequence, the identification of new prognostic molecular biomarkers able to testify tumor aggressiveness is highly required [31,32].

In this context, BRAF^{V600E} mutation, the most prevalent genetic alteration observed in 29–87% of PTC and considered as an early genetic event in thyroid cancer progression received considerable attention as new prognostic marker in PTC [31–33]. However, its association with older age, the detection of the mutation in lymph node-metastasized PTC but not in primary tumors, and the recent demonstration that BRAF^{V600E} is a secondary subclonal rather than a primary event in thyroid tumorigenesis, argue against the proposed primary tumorigenic role of BRAF^{V600E} in PTC [32,34,35]. Nevertheless, several reports described the association of this mutation with factors related to poor prognosis, such as the presence of extrathyroidal extension, lymph node metastasis, advanced tumor stage, reduced disease-free interval and patient survival [31,33]. Despite the initial enthusiasm, a debate is actually ongoing about the clinical relevance of these findings [31,32]. In particular, some studies failed to associate the BRAF^{V600E} with poor prognosis in PTC patients [33,34,36]. In addition, the frequency of BRAF mutation in PTC (on average 50%) is high compared with that of the poor outcomes (about 20%). On the other hand, a recent case-study performed on 977 patients affected by papillary microcarcinoma of the thyroid suggested that the highly aggressive tumors may arise in a subset of patients with the BRAF^{V600E} [37]. From the currently available information it is evident that, based only on the analysis of the BRAF^{V600E} mutation, a large percentage of patients would face the risk of over- or under-treatment. Is thus possible that in a near future the association of BRAF^{V600E} with other clinical and/or molecular marker(s) could lead to a better prognostic definition of PTC patients.

The urokinase plasminogen activating system (uPAS) comprises the urokinase plasminogen activator (uPA), the cell membrane uPA receptor (uPAR) and the plasminogen activator inhibitor-1 (PAI-1) and -2 (PAI-2) [38]. It is involved on different aspects of human cancer progression including extracellular matrix degradation, activation of latent growth factors, malignant cells proliferation and spread to distant metastatic sites, and tumor neo-angiogenesis [38,39]. The prognostic value of uPAS has been demonstrated in different cancer types where overexpression of one or more uPAS components was shown to associate with a higher risk of relapse and poor clinical outcome [38,39]. This is particularly evident in breast cancer, in which uPA and PAI-1 show a predictive value stronger than patient age, tumor size, estrogen and progesterone receptors, HER-2/neu or p53 expression [40–44]. As a consequence, the American Society of Clinical Oncology has included both proteins among the recommended breast tumor markers for clinical use [45]. Over the last two decades, several studies investigated the expression of the uPAS in human thyrocytes [46–49]. Following malignant thyrocyte transformation the aberrant expression of uPAS components has been demonstrated [50–60]. More importantly, it has been evidenced that uPA, its cognate receptor uPAR and PAI-1 significantly associate with high-risk clinicopathological factors such as lymph node metastasis, higher TNM stage, shorter disease-free interval and overall survival [61–65]. Moreover, this association was found statistically stronger in stage I patients [34,61]. These findings may thus help to better define the prognosis, make informed therapeutic decisions and develop tailored prevention programs especially for stage I PTC patients, actually considered at low risk to develop disease recurrences. All together these observations indicate the potential prognostic value of uPAS components in thyroid cancer patients, and warrant further investigations on larger case-studies.

The estrogen receptors (ER) are members of the nuclear steroid receptor superfamily, and mediate cellular responses to estrogens which modulate growth, differentiation and function of different target tissues [66,67]. The ER function as ligand-dependent transcription factors, but they can also have a ligand-independent activity following phosphorylation by kinases [66,67]. Two different genes encode the ER, ERα and ERβ, showing different tissue

distributions and cellular functions, often with opposite effects on cellular proliferation, migration and apoptosis [66,67]. The two ER isoforms may also affect in different ways the development and progression of human cancers, and have been shown to possess a prognostic value in several cancer types including breast, ovarian and lung cancers [68–76]. The expression of the ER has been also described in both normal and neoplastic thyroid tissues and might explain, at least in part, the higher prevalence of thyroid cancer in females with respect to males [77–81]. Accordingly to this hypothesis, Lee and colleagues showed that estradiol induces the proliferation of PTC-derived cells when compared with cells treated with testosterone, and that tamoxifene was able to attenuate the growth-promoting effects of estradiol [82]. The proliferative effects of estradiol on thyroid cancer cells seem to be mediated by the ERα, as mimicked by ERα agonists, while ERβ agonists inhibited cancer cell proliferation [77]. This is in agreement with a recent study showing that the expression of ERα in thyroid cancer is increased, while that of ERβ was undetectable [80]. In addition, Heikkilä and colleagues demonstrated that the reduction of ERβ expression associates significantly with poor outcome in FTC patients suggesting its potential prognostic value in DTC patients [83].

Mature microRNAs (miR) are small (19–25 nucleotides), non-coding RNA molecules that behave as negative regulators of gene expression [84,85]. They regulate a wide variety of cellular functions as proliferation and apoptosis and may act as either tumor suppressor genes or oncogenes [84–88]. Mature miR typically down-regulate gene expression post-transcriptionally by inhibiting mRNA translation or promoting mRNA degradation by annealing to complementary sequences in 3′ untranslated regions of their target mRNAs [85]. In thyroid cancer tissues different miRs were found up-regulated and a number of them were suggested to have a diagnostic utility [89–91]. In particular, the miR-146b was recently shown to associate in PTC with extrathyroidal invasion, advanced tumor stage, BRAF mutation and disease-free survival [92–97].

4. Conclusions and perspectives

In conclusion, different new promising molecular biomarkers possibly capable to predict disease outcome in thyroid cancer patients are emerging. The experimental evidence here reported warrant further clinical investigation to finally prove their prognostic value. Their future inclusion in the clinical practice, alone or in combination with conventional prognostic factors, is likely to ameliorate the actual staging system, allowing a tailored follow-up to the single patient needs.

Ethical approval

This is a review manuscript for which no Ethical Approval was required.

Author contribution

EB: contributed substantially to the first draft of the manuscript and editing.

SS: contributed substantially to the first draft of the manuscript and editing.

CT: contributed substantially to the correction and editing of the manuscript.

NP: contributed substantially to the correction and editing of the manuscript.

CC: contributed substantially to the correction and editing of the manuscript.

AC: contributed substantially to the correction and editing of the manuscript.

AF: contributed substantially to the correction and editing of the manuscript.

MB: contributed substantially to the correction and editing of the manuscript.

EDA: contributed substantially to the first draft of the manuscript and editing.

MDA: contributed substantially to the first draft of the manuscript and editing.

SU: contributed to substantially the first draft of the manuscript and editing.

All authors approve the final version of the manuscript.

Funding

Conflict of interest

The authors have no conflict of interest or any financial support.

References

[1] S.I. Sherman, Thyroid carcinoma, Lancet 361 (2003) 501–511.
[2] A. Jemal, R. Siegel, E. Ward, et al., Cancer statistics, 2009, CA Cancer J. Clin. 59 (2009) 225–249.
[3] P. Trimboli, S. Ulisse, F.M. Graziano, et al., Trend in thyroid carcinoma size, age at diagnosis, and histology in a retrospective study of 500 cases diagnosed over 20 years, Thyroid 16 (2006) 1151–1155.
[4] L. Davies, H.G. Welch, Increasing incidence of thyroid cancer in the United States, 1973–2002, JAMA 295 (2006) 2164–2167.
[5] B.K. Kinder, Well differentiated thyroid cancer, Curr. Opin. Oncol. 15 (2003) 71–77.
[6] J.L. Pasieka, Anaplastic thyroid cancer, Curr. Opin. Oncol. 15 (2003) 78–83.
[7] R. Paschke, L. Hegedüs, E. Alexander, R. Valcavi, E. Papini, H. Gharib, Thyroid nodule guidelines: agreement, disagreement and need for future research, Nat. Rev. Endocrinol. 7 (2011) 354–361.
[8] S.A. Roman, Endocrine tumors: evaluation of the thyroid nodule, Curr. Opin. Oncol. 15 (2003) 66–70.
[9] American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer D.S. Cooper, G.M. Doherty, et al., Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer, Thyroid 19 (2009) 1167–1214.
[10] D. Hanahan, R.A. Weimberg, The hallmark of cancer, Cell 100 (2000) 57–70.
[11] Y.E. Nikiforov, Diagnostic Pathology and Molecular Genetics of the Thyroid, Lippincott Williams & Wilkins, Philadelphia, 2009.
[12] Y.E. Nikiforov, M.N. Nikiforova, Molecular genetics and diagnosis of thyroid cancer, Nat. Rev. Endocrinol. 7 (2011) 569–580.
[13] B. Shahedian, Y. Shi, M. Zou, N.R. Farid, Thyroid carcinoma is characterized by genomic instability: evidence from p53 mutations, Mol. Genet. Metab. 72 (2001) 155–163.
[14] V.B. Wressmann, R.A. Ghossein, S.G. Patel, et al., Genome-wide appraisal of thyroid cancer progression, Am. J. Pathol. 161 (2002) 1549–1556.
[15] K.N. Patel, A.R. Shaha, Poorly differentiated and anaplastic thyroid cancer, Cancer Control 13 (2006) 119–128.
[16] J.A. Fagin, Minireview: branded from the start-distinct oncogenic initiating events may determine tumor fate in the thyroid, Mol. Endocrinol. 16 (2002) 903–911.
[17] B. Ouyang, J.A. Knauf, K. Ain, B. Nacev, J.A. Fagin, Mechanisms of aneuploidy in thyroid cancer cell lines and tissues: evidence for mitotic checkpoint dysfunction without mutations in BUB1 and BUBR1, Clin. Endocrinol. 56 (2002) 341–350.
[18] Y. Ito, E. Miyoshi, N. Sasaki, et al., Polo-like kinase 1 overexpression is an early event in the progression of papillary carcinoma, Br. J. Cancer 90 (2004) 414–418.
[19] S. Ulisse, J.G. Delcros, E. Baldini, et al., Expression of Aurora kinases in human thyroid carcinoma cell lines and tissues, Int. J. Cancer 119 (2006) 275–282.
[20] S. Ulisse, J.G. Delcros, E. Baldini, et al., Transforming acidic coiled-coil 3 and Aurora-A interact in human thyrocytes and their expression is deregulated in thyroid cancer tissues, Endocr. Relat. Cancer 14 (2007) 831–842.
[21] M.A. Huber, N. Kraut, H. Beug, Molecular requirements for epithelial-mesenchymal transition during tumor progression, Curr. Opin. Cell Biol. 17 (2005) 548–558.
[22] V. Vasko, A.V. Espinosa, W. Scouten, et al., Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion, Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 2803–2808.

[23] M. Schlumberger, G. Berg, O. Cohen, et al., Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective, Eur. J. Endocrinol. 150 (2004) 105—112.

[24] F. Pacini, M. Schlumberger, H. Dralle, R. Elisei, J.W. Smit, W. Wiersinga, European Thyroid Cancer Taskforce: European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium, Eur. J. Endocrinol. 154 (2006) 787—803.

[25] C.F. Eustatia-Rutten, E.P. Corssmit, N.R. Biermasz, A.M. Pereira, J.A. Romijn, J.W. Smit, Survival and death causes in differentiated thyroid carcinoma, J. Clin. Endocrinol. Metab. 91 (2006) 313—319.

[26] M.K. Gospodarowicz, D.E. Henson, R.V.P. Hutter, B. O'Sullivan, L.H. Sobin, C.L. Wittekind, Prognostic Factors in cancer, second ed., Wiley-Liss, New York, 2001.

[27] C. Passler, C. Scheuba, G. Prager, et al., Prognostic factors of papillary and follicular thyroid cancers: differences in an iodine-replete endemic goiter region, Endocr. Relat. Cancer 11 (2004) 131—139.

[28] 2009 AJCC Cancer Staging Manual, seventh ed., Springer-Verlag, New York, 2009.

[29] F. Pacini, M.G. Castagna, L. Brilli, G. Pentheroudakis, on behalf of the ESMO Guidelines Working Group, Thyroid cancer: ESMO clinical practice guidelines for diagnosis treatment and follow-up, Ann. Oncol. 23 (2012) 110—119.

[30] M.G. Castagna, F. Maino, C. Cipri, et al., Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients, Eur. J. Endocrinol. 165 (2011) 441—446.

[31] D. Handkiewicz-Junak, A. Czarniecka, B. Jarząb, Molecular prognostic markers in papillary thyroid cancer: current status and future directions, Mol. Cell. Endocrinol. 322 (2010) 8—28.

[32] D. Shibru, K.W. Chung, E. Kebebew, Recent developments in the clinical application of thyroid cancer biomarkers, Curr. Opin. Oncol. 20 (2008) 13—18.

[33] M. Xing, BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications, Endocr. Rev. 28 (2007) 742—762.

[34] S. Ulisse, E. Baldini, S. Sorrenti, et al., In papillary thyroid carcinoma BRAFV600E is associated with increased expression of the urokinase plasminogen activator and its cognate receptor, but not with disease-free interval, Clin. Endocrinol. 77 (2012) 780—786.

[35] A. Guerra, M.R. Sapio, V. Marotta, et al., The primary occurrence of BRAFV600E is a rare clonal event in papillary thyroid carcinoma, J. Clin. Endocrinol. Metab. 97 (2012) 517—524.

[36] Y. Ito, H. Yoshida, R. Maruo, et al., BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients, Endocr. J. 56 (2009) 89—97.

[37] X. Zheng, S. Wei, Y. Han, et al., Papillary microcarcinoma of the thyroid: clinical characteristics and BRAF(V600E) mutational status of 977 cases, Ann. Surg. Oncol. 20 (2013) 2266—2273.

[38] S. Ulisse, E. Baldini, S. Sorrenti, M. D'Armiento, The urokinase plasminogen activator system: a target for anti-cancer therapy, Curr. Cancer Drug Targets 9 (2009) 32—71.

[39] M.J. Duffy, The urokinase plasminogen activator system: role in malignancy, Curr. Pharm. Des. 10 (2004) 39—49.

[40] F. Jänicke, A. Prechtl, C. Thomssen, et al., Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1, J. Natl. Cancer Inst. 93 (2001) 913—920.

[41] M.J. Duffy, Urokinase-type plasminogen activator: a potent marker of metastatic potential in human cancer, Biochem. Soc. Trans. 30 (2002) 207—210.

[42] M. Schmitt, N. Harbeck, C. Thomssen, et al., Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy, Thromb. Haemost. 78 (1997) 285—296.

[43] M.P. Look, W.L. van Putten, M.J. Duffy, et al., Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients, J. Natl. Cancer Inst. 94 (2002) 116—128.

[44] J.A. Foekens, H.A. Peters, M.P. Look, et al., The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients, Cancer Res. 60 (2000) 636—643.

[45] L. Harris, H. Fritsche, R. Mennel, et al., American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer, J. Clin. Oncol. 25 (2007) 5287—5312.

[46] J.D. Ramsden, S. Yarram, E. Mathews, J.C. Watkinson, M.C. Eggo, Thyroid follicular cells secrete plasminogen activators and can form angiostatin from plasminogen, J. Endocrinol. 173 (2002) 475—481.

[47] P. Ragno, N. Montuori, S. Salzano, G. Rossi, Urokinase-type plasminogen-activator and normal thyroid cell adhesion to the extracellular matrix, Biochimie 81 (1999) 355—358.

[48] N. Montuori, G. Rossi, P. Ragno, Cleavage of urokinase receptor regulates its interaction with integrins in thyroid cells, FEBS Lett. 460 (1999) 32—36.

[49] N. Montuori, S. Salzano, G. Rossi, P. Ragno, Urokinase-type plasminogen activator up-regulates the expression of its cellular receptor, FEBS Lett. 476 (2000) 166—170.

[50] Y. Ito, T. Takeda, T. Kobayashi, et al., Plasminogen activation system is active even in thyroid tumors; an immunohistochemical study, Anticancer Res. 16 (1996) 81—89.

[51] K.S. Packman, M.J. Demeure, K.M. Doffek, S.D. Wilson, Increased plasminogen activator and type IV collagenase activity in invasive follicular thyroid carcinoma cells, Surgery 118 (1995) 1011—1016.

[52] S.J. Kim, E. Shiba, T. Taguchi, et al., uPA receptor expression in benign and malignant thyroid tumors, Anticancer Res. 22 (2002) 387—393.

[53] A. Zanetti, A. Stoppacciaro, A. Marzullo, et al., Expression of Met protein and urokinase-type plasminogen activator receptor (uPA-R) in papillary carcinoma of the thyroid, J. Pathol. 186 (1998) 287—291.

[54] J.W. Smith, G. van der Pluijm, H.A. Romijn, C.W. Lowik, H. Morreau, B.M. Goslings, Degradation of extracellular matrix by metastatic follicular thyroid carcinoma cell lines: role of the plasmin activation system, Thyroid 9 (1999) 913—919.

[55] S. Ulisse, E. Baldini, M. Toller, et al., Differential expression of the components of the plasminogen activating system in human thyroid tumor derived cell lines and papillary carcinomas, Eur. J. Cancer 42 (2006) 2631—2638.

[56] T.S. Nowicki, N.T. Kummer, C. Iacob, et al., Inhibition of uPAR and uPA reduces invasion in papillary thyroid carcinoma cells, Laryngoscope 120 (2010) 1383—1390.

[57] T.S. Nowicki, H. Zhao, Z. Darzynkiewicz, et al., Downregulation of uPAR inhibits migration, invasion, proliferation, FAK/PI3K/Akt signaling and induces senescence in papillary thyroid carcinoma cells, Cell Cycle 10 (2011) 100—107.

[58] B. Sid, B. Langlois, H. Sartelet, G. Bellon, S. Dedieu, L. Martiny, Thrombospondin-1 enhances human thyroid carcinoma cell invasion through urokinase activity, Int. J. Biochem. Cell. Biol. 40 (2008) 1890—1900.

[59] B. Sid, S. Dedieu, N. Delorme, et al., Human thyroid carcinoma cell invasion is controlled by the low density lipoprotein receptor-related protein-mediated clearance of urokinase plasminogen activator, Int. J. Biochem. Cell. Biol. 38 (2006) 1729—1740.

[60] Q.D. Chu, T.C. Hurd, S. Harvey, et al., Overexpression of urinary plasminogen activator (uPA) protein and mRNA in thyroid carcinogenesis, Diagn. Mol. Pathol. 13 (2004) 241—246.

[61] S. Ulisse, E. Baldini, S. Sorrenti, et al., High expression of the urokinase plasminogen activator and its cognate receptor associates with advanced stages and reduced disease-free interval in papillary thyroid carcinoma, J. Clin. Endocrinol. Metab. 96 (2011) 504—508.

[62] D. Buergy, T. Weber, G.D. Maurer, G. Mudduluru, F. Medved, J.H. Leupold, et al., Urokinase receptor, MMP-1 and MMP-9 are markers to differentiate prognosis, adenoma and carcinoma in thyroid malignancies, Int. J. Cancer 125 (2009) 894—901.

[63] E. Baldini, S. Sorrenti, E. D'Armiento, F.M. Di Matteo, A. Catania, S. Ulisse, The urokinase plasminogen activating system in thyroid cancer: clinical implications, G. Chir. 33 (2012) 305—310.

[64] G. Horvatić Herceg, D. Herceg, M. Kralik, Z. Bence-Zigman, H. Tomić-Brzac, A. Kulić, Urokinase-type plasminogen activator and its inhibitor in thyroid neoplasms: a cytosol study, Wien. Klin. Wochenschr. 118 (2006) 601—609.

[65] G. Horvatić Herceg, D. Herceg, M. Kralik, et al., Urokinase plasminogen activator and its inhibitor type-1 as prognostic factors in differentiated thyroid carcinoma patients, Otolaryngol. Head Neck Surg. 149 (2013) 533—540.

[66] J.D. Blaustein, Steroid hormone receptors: long- and short-term integrators of the internal milieu and the external environment, Horm. Metab. Res. 44 (2012) 563—568.

[67] S. Mosselman, J. Polman, R. Dijkema, ER beta:identification and characterization of a novel human estrogen receptor, FEBS Lett. 392 (1996) 49—53.

[68] G.G. Chen, Q. Zeng, G.M. Tse, Estrogen and its receptor in cancer, Med. Res. Rev. 28 (2008) 954—974.

[69] F. Wu, R. Xu, K. Kim, J. Martin, S. Safe, In vivo profiling of estrogen receptor/specificity protein-dependent transactivation, Endocrinology 149 (2008) 5696—5705.

[70] S. Ali, R.C. Coombes, Estrogen receptor alpha in human breast cancer: occurrence and significance, J. Mammary Gland Biol. Neoplasia 5 (2000) 271—281.

[71] A. Halon, E. Nowak-Markwitz, A. Maciejczyk, et al., Loss estrogen receptor beta expression correlates with shorter overall survival and lack of clinical response to chemotherapy in ovarian cancer patients, Anticancer Res. 31 (2011) 711—718.

[72] H. Kawai, A. Ishii, K. Washiya, et al., Estrogen receptor alpha and beta are prognostic factors in non-small cell lung cancer, Clin. Cancer Res. 11 (2000) 5084—5089.

[73] Y. Omoto, S. Inoue, S. Ogawa, et al., Clinical value of wild-type estrogen receptor beta expression in breast cancer, Cancer Lett. 163 (2001) 207—212.

[74] A. Halon, V. Materna, M. Drag-Zalesinska, et al., Estrogen receptor alpha expression in ovarian cancer predicts longer survival, Pathol. Oncol. Res. 17 (2011) 511—518.

[75] L.V. Mauro, M. Dalurzo, M.J. Carlini, et al., Estrogen receptor beta and epidermal growth factor receptor as early-stage prognostic biomarkers of non-small cell lung cancer, Oncol. Rep. 24 (2010) 1331—1338.

[76] A. de la Chapelle, K. Jazdzewski, MicroRNAs in thyroid cancer, J. Clin. Endocrinol. Metab. 96 (2011) 3326—3336.

[77] Q. Zeng, G.G. Chen, A.C. Vlantis, C.A. van Hasselt, Oestrogen mediates the growth of human thyroid carcinoma cells via an oestrogen receptor-ERK pathway, Cell Prolif. 40 (2007) 921—935.

[78] S. Rajoria, R. Suriano, A. Shanmugam, et al., Metastatic phenotype is regulated by estrogen in thyroid cells, Thyroid 20 (2010) 33—41.

[79] L. Dalla Valle, A. Ramina, S. Vianello, A. Fassina, P. Belvedere, L. Colombo, Potential for estrogen synthesis and action in human normal and neoplastic thyroid tissues, J. Clin. Endocrinol. Metab. 83 (1998) 3702—3709.

[80] M. Di Vito, E. De Santis, G.A. Perrone, et al., Overexpression of estrogen receptor-α in human papillary thyroid carcinomas studied by laser-capture microdissection and molecular biology, Cancer Sci. 102 (2011) 1921—1927.

[81] S.H. Golden, A. Brown, J.A. Cauley, et al., Health disparities in endocrine disorders: biological, clinical, and nonclinical factors — an endocrine society statement, J. Clin. Endocrinol. Metab. 97 (2012) E1579—E1639.

[82] M.L. Lee, G.G. Chen, A.C. Vlantis, G.M. Tse, B.C. Leung, C.A. van Hasselt, Induction of thyroid papillary carcinoma cell proliferation by estrogen is associated with an altered expression of Bcl-xL, Cancer J. 11 (2005) 113—121.

[83] A. Heikkilä, J. Hagström, H. Mäenpää, et al., Loss of estrogen receptor Beta expression in follicular thyroid carcinoma predicts poor outcome, Thyroid 23 (2013) 456—465.

[84] D.P. Bartel, MicroRNAs: genomics, biogenesis, mechanism, and function, Cell 116 (2004) 281—297.

[85] D.P. Bartel, MicroRNAs: target recognition and regulatory functions, Cell 136 (2004) 215—233.

[86] S.A. Melo, M. Esteller, Disruption of microRNA nuclear transport in human cancer, Semin. Cancer Biol. (2014), http://dx.doi.org/10.1016/j.semcancer.2014.02.012.

[87] H. Jiang, G. Zhang, J.H. Wu, C.P. Jiang, Diverse roles of miR-29 in cancer, Oncol. Rep. 31 (2014) 1509—1516.

[88] J. Liu, W. Shi, C. Wu, J. Ju, J. Jiang, miR-181b as a key regulator of the oncogenic process and its clinical implications in cancer, Biomed. Rep. 2 (2014) 7—11.

[89] L. Lodewijk, A.M. Prins, J.W. Kist, et al., The value of miRNA in diagnosing thyroid cancer: a systematic review, Cancer Biomark. 11 (2012) 229—238.

[90] M.N. Nikiforova, G.C. Tseng, S. Steward, D. Diorio, Y.E. Nikiforov, MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility, J. Clin. Endocrinol. Metab. 93 (2008) 1600—1608.

[91] B. Woitas, C. Ferraz, T. Stokowy, et al., Differential miRNA expression defines migration and reduced apoptosis in follicular thyroid carcinomas, Mol. Cell. Endocrinol. 388 (2014) 1—9.

[92] C.K. Chou, R.F. Chen, F.F. Chou, et al., miR-146b is highly expressed in adult papillary thyroid carcinomas with high risk features including extrathyroidal invasion and the BRAF(V600E) mutation, Thyroid 20 (2010) 489—494.

[93] B. Amato, R. Compagna, L. Sivero, V. Salvati, M. Amato, G. Vigliotti, A. Rocca, M. Donisi, Lymphectomy for elderly in thyroid surgery, Chirurgia 26 (4) (2013 Aug) 303—306.

[94] G. Romano, E. Luna, G. Cocchiara, F. Calderone, C. Zumbino, M. Muzio, M.C. Lo Nigro, A.I. Lo Monte, G. Buscemi, C. Di Bernardo, N. Napoli, The surgical treatment of nodular thyroid lesions: our experience. Analysis of 462 cases, G. Chir. 25 (1—2) (2004 Jan-Feb) 23—26 (Review).

[95] A. Sanguinetti, G. Docimo, M. Ragusa, F. Calzolari, F. D'Ajello, R. Ruggiero, D. Parmeggiani, A. Pezzolla, E. Procaccini, N. Avenia, Ultrasound scissors versus electrocautery in axillary dissection: our experience, G. Chir. 31 (4) (2010 Apr) 151—153. PubMed PMID: 20444331.

[96] R. Gervasi, G. Orlando, M.A. Lerose, B. Amato, G. Docimo, P. Zeppa, A. Puzziello, Thyroid surgery in geriatric patients: a literature review, BMC Surg. 12 (Suppl. 1) (2012) S16, http://dx.doi.org/10.1186/1471-2482-12-S1-S16.

[97] C.K. Chou, K.D. Yang, F.F. Chou, et al., Prognostic implications of miR-146b expression and its functional role in papillary thyroid carcinoma, J. Clin. Endocrinol. Metab. 98 (2013) E196—E205.